Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Colon specific" patented technology

Colonic delivery using Zn/pectin beads with a Eudragit coating

Drug delivery systems that can deliver therapeutic and/or diagnostic agents to the colon are disclosed. The systems include pectin beads crosslinked with zinc or any divalent cation of interest, which beads are then coated with Eudragit®-type polymers. The drug delivery systems are orally administrable, but can deliver the active agents to the colon. In some embodiments, they can administer the agents to various positions in the gastro-intestinal tract, including the colon. The agent can be a small molecule, peptide, protein, nucleic acid, or complex structures of natural, recombinant or synthetic origin. In still other embodiments, the agent is a diagnostic agent. The agents can be used to diagnose, treat or investigate humans and animals for a variety of conditions, including infectious diseases, inflammatory diseases, cancers and the like. Colon-specific delivery is obtained by formulating a prophylactic, therapeutic, and/or diagnostic agent with specific polymers that degrade in the colon, such as pectin. The pectin is gelled/crosslinked with a cation such as a zinc cation. The formulation, typically in the form of ionically crosslinked pectin beads, is subsequently coated with a specific polymer such as a Eudragit® polymer. Processes for obtaining such beads are also disclosed.
Owner:DA VOLTERRA FACULTE DE MEDECINE BICHAT

Colon Specific Gene and Protein and Cancer

Human Colon Specific Polynucleotides (DNA and RNA), Polypeptides, and Antibodies, as well as methods for using and producing such polynucleotides, polypeptides, and antibodies are disclosed. More particularly, methods are disclosed for utilizing such polynucleotides, polypeptides, and antibodies to detect, diagnose, prevent, treat, and / or ameliorate cancer (particularly gastrointestinal tract cancers such as colon and pancreatic cancer). Also disclosed are compositions and methods for targeting and destroying cancer cells (particularly gastrointestinal tract cancers such as colon and pancreatic cancer) via the Colon Specific Protein and / or via the Colon Specific Protein Receptor. Moreover, methods of screening for antagonists and binding partners of the Colon Specific Protein and therapeutic uses of such antagonists and binding partners are also disclosed.
Owner:HUMAN GENOME SCI INC

Novel pH-dependent colon-specific drug delivery system

The invention relates to a novel pH-dependent colon-specific drug delivery system, which adopts pH-dependent colon-specific drug delivered polymer thin film coating material as the main coating material, a tablet core forms a hydrophilic gel frame structure, the coating film can be dissolved at specific parts (part is dissolved at the tail end of small intestine and the most is dissolved at the colon part) according to the condition of high pH (pH is more than 7.2) of the tail end of small intestine and the colon part, so as to play the role of colon-specific drug delivery. The invention is based on the principles of chrono-pharmacology and human physiology, which can ensure the pH-dependent colon-specific drug delivered polymer thin film coating material to be released slowly and for 12 hours in a sustained way after the dissolution at least, so as to achieve the oral colon-specific slow release effect.
Owner:TIANJIN MEDICAL UNIV

Method for preparing colon positioning compression-coated tablets

InactiveCN101433525AColon-localized drug release effect is obviousRegulated drug release processPharmaceutical delivery mechanismPharmaceutical non-active ingredientsCarrageenanAdhesive
The invention discloses a method for preparing a colon-specific pressed coated tablet. The method comprises the following steps: (1) mixing Konjac Glucomannan, xanthan gum or carrageenan and a diluting agent; adding an adhesive to the mixture, pelletizing the mixture by a wet method, drying the mixture until constant weight, finishing pellets, and adding a lubricating agent to the mixture to evenly mix, so as to obtain a coating material of the colon-specific pressed coated tablet; (2) evenly mixing bulk drugs and a disintegrant, adding an adhesive to the mixture, pelletizing the mixture by the wet method, drying the mixture until constant weight, finishing pellets, and adding the lubricating agent to the mixture to evenly mix, so as to obtain a drug-contained tablet core; and (3) coating the coating material of the colon-specific pressed coated tablet outside the drug-contained tablet core to be prepared into the colon-specific pressed coated tablet. The colon-specific pressed coated tablet prepared by the method has the characteristic of obvious colon-specific release effect, can conveniently regulate the release process of the tablet through changing the thickness of a coating outer layer, the proportion of blending amylose and the content of the diluting agent. The method has the advantages of wide drug loading system, wide raw material source, low price and simple preparation process.
Owner:TIANJIN UNIV

Segmented intestine targeted preparation of animal skin glue collagen polypeptide and method of preparing the same

The invention provides a colon specific targeting preparation of animal skin collagen polypeptides and its preparing process, wherein the preparation is prepared through coating the drug-containing micro-pellets containing animal skin collagen polypeptides components with colon targeting coating liquid, or directly loading the drug-containing micro-pellets into the shells of the colon targeting capsule. The preparation provided by the invention can make the colon release drugs enter blood circulation through colon, thereby avoiding metabolism destruction of the conventional oral preparation peptides drugs on the stomach, as a result, the therapeutic action of the drugs can be sufficiently exploited.
Owner:李立

Starch based segmented intestine targeting specific adhesion material, preparation and application thereof

The invention discloses a starch based colon idiosyncratic adhesion material for coupling concanavalin A and a method for preparing the same. The anti-digestion starch undergoes the activating treatment by glutaraldehyde, couples with the concanavalin A and is subjected to centrifuge washing by phosphate buffer and inactivation by ethanolamine to obtain the starch based colon idiosyncratic adhesion material. The invention also discloses application of the starch based colon targeting idiosyncratic adhesion material in preparing biomacromolecule medicines of polypeptide protein or medicines of treating colon diseases. For the first time, the invention utilizes the characteristics of the idiosyncratic adsorption between the concanavalin A and the colon epithelial cell, successfully prepares the carrier material of the starch based colon idiosyncratic adhesion material by coupling the concanavalin A with the anti-digestion starch molecule by the glutaraldehyde and uses the starch based colon idiosyncratic adhesion material as an oral taking colon targeting control-release carrier material, so that starch based colon idiosyncratic adhesion material and the method have the characteristics of cell adsorption, enzymolysis triggering targeting, good biocompatibility, safety and non-toxin, good targeting slow-release effect, and the like.
Owner:SOUTH CHINA UNIV OF TECH

Gambogic acid colon-specific controlled release tablet and preparation method thereof

The invention relates to a gambogic acid colon-specific controlled release tablet and a preparation method thereof. The colon-specific controlled release tablet comprises a tablet core and a coating layer; the tablet core comprises the following material in percentage by weight: 1 to 60 percent of gambogic acid, 2 to 95 percent of diluent adjuvant, 2 to 20 percent of disintegration adjuvant, 1 to 20 percent of adhesion adjuvant, and 0.1 to 5 percent of lubricating adjuvant; and the coating layer comprises the following material in percentage by weight: 15 to 80 percent of polysaccharide compound, 15 to 80 percent of adhesion adjuvant, and 0.2 to 5 percent of lubricating adjuvant. The polysaccharide compound of the coating layer preferably adopts one of pectin and konjac glucomannan. The preparation method comprises the steps of tablet core preparation and coating layer preparation. The gambogic acid colon-specific controlled release tablet can accurately transfer drug to colon, improves the treatment effect of colon cancer, reduces the side effect, and improves the compliance of patients.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products